Purple Biotech Ltd ADR (PPBT) — Titan Protect Analysis

PPBT

Purple Biotech Ltd ADR

Healthcare · ·

$2.97

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3M

Total market value of the company

Trailing P/E

0.00

Very cheap relative to earnings

Forward P/E

-3.42

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-123.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.00

+910% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Purple Biotech Ltd ADR

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small

https://purple-biotech.com

Country: Israel Employees: 10 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.625

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1094

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.861

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-84.2%

Historical annualised return based on price data

Max Drawdown

-97.8%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

129

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.57

Very low correlation to market moves

52W High

$29.00

90% below the year high

52W Low

$2.52

18% above the year low

Avg Volume

115,933

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$3,226.00

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.90

Meaningful debt load — monitor closely

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-2,496,125

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-26,019,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$30.00

Target Median

$30.00

Target Low

$30.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go